Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha Sells 55,000 Shares

Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) CEO Saurabh Saha sold 55,000 shares of the business's stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $16.69, for a total value of $917,950.00. Following the completion of the sale, the chief executive officer now owns 276,017 shares of the company's stock, valued at $4,606,723.73. The trade was a 16.62 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Saurabh Saha also recently made the following trade(s):

• On Thursday, February 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $15.93, for a total transaction of $876,150.00.
• On Tuesday, January 21st, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $15.77, for a total transaction of $867,350.00.

Centessa Pharmaceuticals Stock Down 4.9 %

CNTA stock traded down $0.82 during trading on Tuesday, hitting $15.81. 785,408 shares of the stock traded hands, compared to its average volume of 528,206. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. The stock has a market cap of $2.08 billion, a price-to-earnings ratio of -10.33 and a beta of 1.54. Centessa Pharmaceuticals plc has a 1 year low of $7.75 and a 1 year high of $19.09. The firm's 50 day moving average is $16.49 and its two-hundred day moving average is $16.42.

Remove Ads

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its quarterly earnings results on Monday, March 24th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.04. On average, sell-side analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Price T Rowe Associates Inc. MD boosted its position in shares of Centessa Pharmaceuticals by 14.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,364,392 shares of the company's stock valued at $89,854,000 after buying an additional 685,371 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its holdings in shares of Centessa Pharmaceuticals by 22.0% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,119,027 shares of the company's stock valued at $85,744,000 after acquiring an additional 924,027 shares during the last quarter. Janus Henderson Group PLC grew its stake in shares of Centessa Pharmaceuticals by 279.2% in the fourth quarter. Janus Henderson Group PLC now owns 4,909,487 shares of the company's stock worth $82,218,000 after acquiring an additional 3,614,623 shares during the period. Farallon Capital Management LLC lifted its position in Centessa Pharmaceuticals by 24.3% during the fourth quarter. Farallon Capital Management LLC now owns 3,498,709 shares of the company's stock valued at $58,603,000 after purchasing an additional 684,391 shares during the period. Finally, Point72 Asset Management L.P. boosted its holdings in Centessa Pharmaceuticals by 26.2% in the fourth quarter. Point72 Asset Management L.P. now owns 3,426,599 shares of the company's stock worth $57,396,000 after purchasing an additional 710,936 shares during the last quarter. Hedge funds and other institutional investors own 82.01% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on CNTA. Morgan Stanley restated an "overweight" rating and set a $27.00 target price on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Guggenheim restated a "buy" rating on shares of Centessa Pharmaceuticals in a report on Monday, February 10th. Finally, TD Cowen started coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They set a "buy" rating on the stock. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, Centessa Pharmaceuticals presently has a consensus rating of "Buy" and an average price target of $26.00.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.